An anthracenedione-derived antineoplastic agent.
Compounds based on ANTHRACENES which contain two KETONES in any position. Substitutions can be in any position except on the ketone groups.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Substances that inhibit or prevent the proliferation of NEOPLASMS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A family of MEMBRANE TRANSPORT PROTEINS that require ATP hydrolysis for the transport of substrates across membranes. The protein family derives its name from the ATP-binding domain found on the protein.
Simultaneous resistance to several structurally and functionally distinct drugs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE).
An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
An antimitotic agent with immunosuppressive properties.
Compounds that inhibit the activity of DNA TOPOISOMERASES.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Agents that are capable of inserting themselves between the successive bases in DNA, thus kinking, uncoiling or otherwise deforming it and therefore preventing its proper functioning. They are used in the study of DNA.
A group of diterpenoid CYCLODECANES named for the taxanes that were discovered in the TAXUS tree. The action on MICROTUBULES has made some of them useful as ANTINEOPLASTIC AGENTS.
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.
Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.
Tumors or cancer of the PROSTATE.
DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
An anti-inflammatory 9-fluoro-glucocorticoid.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
The former British crown colony located off the southeast coast of China, comprised of Hong Kong Island, Kowloon Peninsula, and New Territories. The three sites were ceded to the British by the Chinese respectively in 1841, 1860, and 1898. Hong Kong reverted to China in July 1997. The name represents the Cantonese pronunciation of the Chinese xianggang, fragrant port, from xiang, perfume and gang, port or harbor, with reference to its currents sweetened by fresh water from a river west of it.
A publication issued at stated, more or less regular, intervals.
A drive stemming from a physiological need for WATER.
An imprecise term which may refer to a sense of spatial disorientation, motion of the environment, or lightheadedness.
A filament-like structure consisting of a shaft which projects to the surface of the SKIN from a root which is softer than the shaft and lodges in the cavity of a HAIR FOLLICLE. It is found on most surfaces of the body.
Discharge of URINE, liquid waste processed by the KIDNEY, from the body.
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM.
Drugs that cannot be sold legally without a prescription.
The largest country in North America, comprising 10 provinces and three territories. Its capital is Ottawa.
Insurance providing for payment of services rendered by the pharmacist. Services include the preparation and distribution of medical products.
Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.
Directions written for the obtaining and use of DRUGS.
A 191-amino acid polypeptide hormone secreted by the human adenohypophysis (PITUITARY GLAND, ANTERIOR), also known as GH or somatotropin. Synthetic growth hormone, termed somatropin, has replaced the natural form in therapeutic usage such as treatment of dwarfism in children with growth hormone deficiency.

Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. (1/750)

BACKGROUND: Human cancer cell lines grown in the presence of the cytotoxic agent mitoxantrone frequently develop resistance associated with a reduction in intracellular drug accumulation without increased expression of the known drug resistance transporters P-glycoprotein and multidrug resistance protein (also known as multidrug resistance-associated protein). Breast cancer resistance protein (BCRP) is a recently described adenosine triphosphate-binding cassette transporter associated with resistance to mitoxantrone and anthracyclines. This study was undertaken to test the prevalence of BCRP overexpression in cell lines selected for growth in the presence of mitoxantrone. METHODS: Total cellular RNA or poly A+ RNA and genomic DNA were isolated from parental and drug-selected cell lines. Expression of BCRP messenger RNA (mRNA) and amplification of the BCRP gene were analyzed by northern and Southern blot hybridization, respectively. RESULTS: A variety of drug-resistant human cancer cell lines derived by selection with mitoxantrone markedly overexpressed BCRP mRNA; these cell lines included sublines of human breast carcinoma (MCF-7), colon carcinoma (S1 and HT29), gastric carcinoma (EPG85-257), fibrosarcoma (EPF86-079), and myeloma (8226) origins. Analysis of genomic DNA from BCRP-overexpressing MCF-7/MX cells demonstrated that the BCRP gene was also amplified in these cells. CONCLUSIONS: Overexpression of BCRP mRNA is frequently observed in multidrug-resistant cell lines selected with mitoxantrone, suggesting that BCRP is likely to be a major cellular defense mechanism elicited in response to exposure to this drug. It is likely that BCRP is the putative "mitoxantrone transporter" hypothesized to be present in these cell lines.  (+info)

Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. (2/750)

Selection for in vitro drug resistance can result in a complex phenotype with more than one mechanism of resistance emerging concurrently or sequentially. We examined emerging mechanisms of drug resistance during selection with mitoxantrone in the human myeloma cell line 8226. A novel transport mechanism appeared early in the selection process that was associated with a 10-fold resistance to mitoxantrone in the 8226/MR4 cell line. The reduction in intracellular drug concentration was ATP-dependent and ouabain-insensitive. The 8226/MR4 cell line was 34-fold cross-resistant to the fluorescent aza-anthrapyrazole BBR 3390. The resistance to BBR 3390 coincided with a 50% reduction in intracellular drug concentration. Confocal microscopy using BBR 3390 revealed a 64% decrease in the nuclear:cytoplasmic ratio in the drug-resistant cell line. The reduction in intracellular drug concentration of both mitoxantrone and BBR 3390 was reversed by a novel chemosensitizing agent, fumitremorgin C. In contrast, fumitremorgin C had no effect on resistance to mitoxantrone or BBR 3390 in the P-glycoprotein-positive 8226/DOX6 cell line. Increasing the degree of resistance to mitoxantrone in the 8226 cell line from 10 to 37 times (8226/MR20) did not further reduce the intracellular drug concentration. However, the 8226/MR20 cell line exhibited 88 and 70% reductions in topoisomerase II beta and alpha expression, respectively, compared with the parental drug sensitive cell line. This decrease in topoisomerase expression and activity was not observed in the low-level drug-resistant, 8226/MR4 cell line. These data demonstrate that low-level mitoxantrone resistance is due to the presence of a novel, energy-dependent drug efflux pump similar to P-glycoprotein and multidrug resistance-associated protein. Reversal of resistance by blocking drug efflux with fumitremorgin C should allow for functional analysis of this novel transporter in cancer cell lines or clinical tumor samples. Increased resistance to mitoxantrone may result from reduced intracellular drug accumulation, altered nuclear/cytoplasmic drug distribution, and alterations in topoisomerase II activity.  (+info)

Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. (3/750)

PURPOSE: To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS: Forty-one chemotherapy-naive patients with MBC (median age, 61 years) were enrolled. Thirty-eight (93%) had performance status (World Health Organization [WHO]) 0, 29 (71%) were postmenopausal, and 21 (51%) had estrogen receptor-negative tumors. Patients received escalated doses of docetaxel (75 to 100 mg/m2) on day 1 and mitoxantrone (8 to 22 mg/m2) on day 8. Treatment was repeated every 3 weeks. RESULTS: A total of 217 chemotherapy cycles were administered. Without recombinant human granulocyte colony-stimulating factor (rhG-CSF) support, the MTD1 occurred at the first dose level (docetaxel 75 mg/m2 and mitoxantrone 8 mg/m2); DLTs were febrile neutropenia, grade 4 neutropenia lasting more than 5 days, and grade 3 diarrhea. With prophylactic rhG-CSF, the MTD2 was docetaxel 100 mg/m2 and mitoxantrone 20 mg/m2; DLTs were febrile neutropenia and grade 4 neutropenia. Nine (22%) patients developed neutropenia after the first cycle of treatment. A total of 19 episodes of febrile neutropenia (9% of the cycles) occurred during the whole period of the study; there were no toxic deaths. At high docetaxel (100 mg/m2) and mitoxantrone (> 12 mg/m2) dose levels, a significant decrease of the absolute lymphocyte number was observed; immunophenotyping revealed that all lymphocyte subpopulations were reduced. Grades 2 and 3 neurosensory toxicity occurred in six patients (15%) and one patient (2%), respectively. No cardiac toxicity was observed. Nine complete responses (22%) and 23 partial responses (56%) were achieved (overall response rate, 78%; 95% confidence interval, 62.5% to 88.8%). The median duration of response was 12.5 months, and the median time to tumor progression was 14.5 months. CONCLUSION: The reported combination of docetaxel and mitoxantrone with G-CSF support is a safe, intensified, well-tolerated, and effective regimen as first-line treatment in patients with MBC.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (4/750)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. (5/750)

It is debated whether follicular large cell lymphoma (FLCL) has a clinical behavior that is distinct from indolent follicular lymphomas, and whether there is a subset of patients who can be potentially cured. We report here our experience with 100 FLCL patients treated at our institution since 1984 with three successive programs. We evaluated the predictive value of pretreatment clinical features, including two risk models, the Tumor Score System and the International Prognostic Index (IPI). With a median follow-up of 67 months, the 5-year survival is 72% and the failure-free survival (FFS) is 67%, with a possible plateau in the FFS curve, particularly for patients with stage I-III disease. Features associated with shorter survival included age >/=60, elevated lactic dehydrogenase (LDH) or beta-2-microglobulin (beta2M), advanced stage, and bone marrow involvement. Stage III patients had significantly better survival than stage IV patients (P <.05). By the IPI and Tumor Score System, 80% of the patients were in the lower risk groups; both systems stratified patients into prognostic groups. Patients with FLCL have clinical features and response to treatment similar to that reported for diffuse large cell lymphoma. Prognostic risk systems for aggressive lymphomas are useful for FLCL. A meaningful fraction of patients may possibly be cured when treated as aggressive lymphomas.  (+info)

Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. (6/750)

OBJECTIVE: To investigate left ventricular dysfunction in patients who had been treated with anthracycline based chemotherapy. METHODS: Autonomic function was compared with left ventricular diastolic function in 20 asymptomatic women with normal systolic function (left ventricular ejection fraction (LVEF) > 0.50) treated for breast cancer with high dose anthracycline based chemotherapy, and 20 age matched healthy controls. Left ventricular diastolic function was assessed echocardiographically by measuring the early peak flow velocity to atrial peak flow velocity ratio, isovolumic relaxation time, and deceleration time. Heart rate variability analysis was assessed for time domain and frequency domain parameters. RESULTS: The mean (SD) age of the patients was 45 (7) years and the mean LVEF was 0.59 (0.06). The time interval after the end of chemotherapy was 29 (27) months. One or more diastolic variables were abnormal in 50% of the patients. Heart rate variability was abnormal in 85% of patients. Mean values of both time domain and frequency domain parameters were decreased (p < 0.05), in particular the parasympathetic indices. CONCLUSIONS: Autonomic impairment occurs in a large proportion of asymptomatic patients with normal systolic left ventricular function after high dose anthracycline based chemotherapy. In particular, heart rate variability analysis may be a sensitive tool to identify the first signs of cardiotoxicity in these patients.  (+info)

Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. (7/750)

BACKGROUND AND OBJECTIVE: High-dose cytarabine (HDAra-C), mitoxantrone and etoposide are the mainstay of several active regimens against relapsed or refractory acute myelogenous leukemia (AML). We designed a phase II study to assess the efficacy and side effects of a time sequential application of mitoxantrone plus intermediate-dose Ara-C followed by HDAra-C plus etoposide (GEMIA) in adult patients with refractory or relapsed AML. DESIGN AND METHODS: Patients with refractory or relapsed AML were eligible for GEMIA salvage therapy, which comprised mitoxantrone 12 mg/m2/day on days 1-3, Ara-C 500 mg/m2/day as a 24-hour continuous infusion on days 1-3, followed by HDAra-C 2 g/m2/12-hourly on days 6-8 and etoposide 100 mg/m2/12-hourly on days 6-8. Granulocyte colony-stimulating factor was started on day 14. In patients above the age of 55 the dose of Ara-C in the first sequence (days 1-3) was reduced to 250 mg/m2. RESULTS: Twenty patients were included, of whom 12 achieved complete remission after GEMIA (60%, 95% CI 40-80%), one was refractory and five died early from infection. Two additional patients achieved partial remission after GEMIA and complete remission after consolidation chemotherapy, for a final CR rate of 70% (95% CI 48-88%). Neutrophils recovered at a median of 27 days (range, 22-43) and platelets 46 days (range, 25-59) after the start of treatment. The median duration of remission was 133 days (range, 36-417+) whereas overall survival time lasted for a median of 153 days (range, 13-554+). Treatment-associated toxicity was comprised predominantly of infection, mucositis and diarrhea that reached World Health Organization grades III-V in 40%, 40% and 30% of patients, respectively. Despite the intention to rapidly proceed to a hematopoietic stem cell transplant in patients in remission, only five patients reached the transplant. INTERPRETATION AND CONCLUSIONS: The GEMIA time sequential chemotherapy regimen appears effective in obtaining remissions in refractory and relapsed adult AML. The high toxicity seen, however, suggests that its design is amenable to further improvements, especially in more elderly patients. Since remissions are short-lived, more innovative post-remission strategies are needed.  (+info)

Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome. (8/750)

Although usually associated with Down's syndrome, transient neonatal myeloproliferation (TMD) can occur in the absence of a constitutional trisomy 21. This report describes two such cases, both of whom had a trisomy 21 restricted to clonal cells. Unlike in previous such reported cases, spontaneous morphological, cytogenetic, and molecular remission in both cases was followed by re-emergence, in one case, of an evolved clone with a more malignant phenotype which required pharmacological intervention. Awareness that trisomy 21 bearing leukaemia in the neonatal period can be transient even in the absence of Down's syndrome is important to prevent unnecessary treatment. Equally, such cases require indefinite follow up as a proportion may have a recurrence which may require treatment.  (+info)

Dive into the research topics of Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma. Together they form a unique fingerprint. ...
Whilst receiving mitoxantrone the chances of you getting an infection are increased. If you begin to have any symptoms of infection, such as fever, chills, sore throat, cough, pain with urinating, or urinating more often, please call your GP or neurology team. MSers who are treated with mitoxantrone are known to be at increased risk of developing a specific type of leukaemia in the future; this an uncommon complication, occurring in approximately 1 in 200-400 subjects with MS who are treated with Mitoxantrone. Clearly female MSers who are pregnant, are trying to become pregnant, or are breastfeeding should not be treated with mitoxantrone because it may harm the baby. You should use birth control while taking mitoxantrone to avoid becoming pregnant. We may have to adjust the dose of mitoxantrone depending on your blood counts. As mitoxantrone is potentially cardiotoxic, or can damage the heart. you will need to have regular testing of your heart and blood to help avoid this serious side effects. ...
Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent. Mitoxantrone is used to treat certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkins lymphoma. It improves the survival rate of children suffering from acute lymphoblastic leukemia relapse. The combination of mitoxantrone and prednisone is approved as a second-line treatment for metastatic hormone-refractory prostate cancer. Until recently this combination was the first line of treatment; however, a combination of docetaxel and prednisone improves survival rates and lengthens the disease-free period. Mitoxantrone is also used to treat multiple sclerosis (MS), most notably the subset of the disease known as secondary-progressive MS. Absent a cure mitoxantrone is effective in slowing the progression of secondary-progressive MS and extending the time between relapses in both relapsing-remitting MS and ...
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases.. This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC. ...
Bone metastases and associated pain are a major cause of morbidity and mortality in castration-resistant prostate cancer (CRPC). Most approved therapies have shown some ability to reduce soft tissue lesions but none meaningfully impacts bone metastases (as demonstrated by lack of resolution of lesions on bone scan with these agents) or the pain associated with these metastases.. This study will evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and bone scan response in men with CRPC. ...
Objective(s): Resistance to medications is one of the main complications in chemotherapy of cancer. It has been shown that some multidrug resistant cancer cells indicate more sensitivity against cytotoxic effects of TNF-α compared to their parental cells. Our previous findings indicated vulnerability of the mitoxantrone-resistant breast cancer cells MCF-7/MX to cell death induced by TNF-α compared to the parent cells MCF-7. In this study, we performed a comparative proteomics analysis for identification of proteins involved in induction of higher susceptibility of MCF-7/MX cells to cytotoxic effect of TNF-α.Materials and Methods: Intensity of protein spots in 2D gel electrophoresis profiles of MCF-7 and MCF-7/MX cells were compared with Image Master Platinum 6.0 software. Selected differential protein-spots were identified with MALDI-TOF/TOF mass spectrometry and database searching. Pathway analyses of identified proteins were performed using PANTHER, KEGG PATHWAY, Gene MANIA and STRING ...
Multiple sclerosis (MS) is a neurodegenerative disease characterized by an autoimmune attack against myelin sheaths in the central nervous system (CNS). Resulting debilitations vary from sensory, motor, and coordination abnormalities to visual difficulties as well as bowel, bladder, sexual, and cognitive dysfunction (Fox, 2006). Mitoxantrone (Novantrone) is an FDAapproved drug used to treat the secondary-progressive form ofMS due to its demonstrated immunosuppressive properties. While the mechanism of action of mitoxantrone is not yet well understood, and is limited in its use due to cardiotoxicity, the aim of this study was to determine the effect of mitoxantrone on microglial and astrocyte activation as a measure of the inflammatory response. Enzyme-linked immunosorbent assays (ELISA) showed that lipopolysaccharide (LPS) stimulates markers of activation including nitric oxide (NO), interleukin-1-beta (IL-l b), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) in N9 cultured
Mitoxantrone (Novantrone), a synthetic anthracenedione derivative, is an antineoplastic, immunomodulatory agent. Its presumed mechanism of action in patients with multiple sclerosis (MS) is via immunomodulatory mechanisms, although these remain to be fully elucidated. Intravenous mitoxantrone treatment improved neurological disability and delayed progression of MS in patients with worsening relapsing-remitting (RR) [also termed progressive-relapsing (PR) MS] or secondary-progressive (SP) disease. In a pivotal randomised, double-blind, multicentre trial, mitoxantrone 12 mg/m(2) administered once every 3 months for 2 years provided significant improvements in neurological disability ratings, including Kurtzke Expanded Disability Status Scale (EDSS), Ambulatory Index (AI) and Standardised Neurological Status (SNS) scores, compared with placebo. The drug also significantly reduced the mean number of corticosteroid-treated relapses and prolonged the time to the first treated relapse, with the ...
BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. METHODS: This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10(-4)
BACKGROUND: Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. METHODS: This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (≥10(-4)
2004 transfer with a little assistance How Do You Deal: I dont have emotional problems. I dont have bladder problems, but bowel is slow. I eat high fiber and take lactulose every day. I get physio therapy twice in a week and three-week rehabilition twice in a year. Possible Cures: In 1994-2001 I have got 40 3-day i.v. methylprednisolon pulses. 7/95-3/96 I used beta-interferon, 6 MIU once a week. During that time I had less fatigue but my ms progressed. I tried gluten free diet in 1993, but it did not help. In 93 I got tetanus-diphteria vaccination. A week after that my walking distance dropped from 500m to 200m. I have been on azathioprine, but have not noticed a difference. Next we will try mitoxantrone treatment. 7/98. After 4 mitoxantrone treatments I am almost stable. 8/2000 After 9 mitoxantrone treatments, I have been active, working part time, my symptoms are only a little worse. 3/2001 Every flu makes me little worse. 10th treatment, two more to go. 10/2003 i got the last mitoxantrone ...
Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the body. Mitoxantrone is used to treat prostate cancer and certain types of leukemia. Mitoxantrone is also used to treat the symptoms of relapsing multiple sclerosis. This medication will not cure multiple sclerosis...
Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the body. Mitoxantrone is used to treat prostate cancer and certain types of leukemia. Mitoxantrone is also used to treat the symptoms of relapsing multiple sclerosis. This medication will not cure multiple sclerosis...
Mitoxantrone information about active ingredients, pharmaceutical forms and doses by Bedford Laboratories, Mitoxantrone indications, usages and related health products lists
Mitoxantrone may be linked to increased risk of colorectal cancer The multiple sclerosis drug mitoxantrone may be associated with an increased risk of colorectal cancer, according to a study published in Neurology, the medical journal of the American Academy of ...
Find information on Mitoxantrone (Novantrone) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
1 Sweeney C., et al. Impact on overall survival with chemohormonal therapy versus hormonal therapy for home-sensitivity newly metastatic prostate cancer: An ECOG-led phase III randomized trial. ASCO 2014; Abstract LBA2.. 2 Tannock I, de Wit R, Berry W, et al.Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 2004; 351:1502-1512.. 3 Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine. 2004; 351:1513-1520.. 4 de Bono JS, Oudard S, Ozguroglu M et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 1147.. 5 Kantoff PW, Higano CS, Shore ND et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411.. 6 Basch E, Autio K, Ryan ...
How Novantrone (mitoxantrone) chemotherapy works, side effects, interactions and precautions. Get free tools to track your health.
Mitoxantrone may cause serious infections, heart problems, or other complications in some people. This eMedTV resource takes an in-depth look at other possible side effects of mitoxantrone and explains which problems require urgent medical care.
8. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer. J Clin Oncol 2005;23(15):3343-3351. ...
Lazienda Steeltecnica nasce oltre 40 anni fa collocandosi nel settore della carpenteria leggera nei comparti elettrici e elettronici sia per il mercato italiano che estero. Opera su una superficie produttiva di 15000 mq situata nella zona industriale di Brivio ( LC ) Dal 2004 è certificata ISO 9001 con lobiettivo di assicurare qualità ed assistenza tecnica alla propria clientela. La consolidata esperienza internazionale, unita al continuo aggiornamento delle strutture tecniche ed ai consistenti investimenti in ricerca e sviluppo, consentono a Steeltecnica di fornire prodotti avanzati ed affidabili. La produzione gestisce una gamma importante di prodotti standard e inoltre, elemento distintivo per Steeltecnica, realizza una serie di prodotti personalizzati su specifiche esigenze del cliente.
Cardiotoxicity from the antitumor anthracycline, doxorubicin, correlates with cardiac drug levels, redox activation, and formation of the metabolite doxorubicinol. The cardiotoxicity may first be observed during salvage therapy with other drugs such as the anthracenedione mitoxantrone. In contrast, less cardiac toxicity has been observed in patients treated with doxorubicin followed by the anthracenedione pixantrone. In doxorubicin-pretreated human myocardial strips, pixantrone or mitoxantrone did not alter levels of residual doxorubicin. Mitoxantrone showed an unchanged uptake but synergized with doxorubicin for more redox formation. In contrast, pixantrone uptake was reduced, lacked redox synergism with doxorubicin, and inhibited formation of doxorubicinol.. See article at J Pharmacol Exp Ther 2013, 344:467-478.. ...
Pixantrone is an anthraquinone-based inhibitor of topoisomerase II. It is similar to both the anthracycline doxorubicin and the anthracenedione mitoxantrone, but lacks the 5,8-dihydroxy substitution pattern of mitoxantrone, and has a tricyclic system unlike the tetracyclic structure seen with anthracyclines. Anthracyclines are the most active drugs in lymphoma therapy, but their use is limited by their cumulative and irreversible cardiotoxicity. Pixantrone was developed to improve the toxicity profile of the current anthracyclines and anthracenediones while maintaining their activity. Interestingly, pixantrone showed no measurable cardiotoxicity compared with its parent compound mitoxantrone or other anthracyclines at equi-effective doses in several animal models. Together with its superior cytotoxic activity in leukaemia and lymphoma models, these features render the drug a promising candidate for clinical development in indolent and aggressive non-Hodgkins lymphoma. In this review, the latest results
1.. Au W-Y, Chan L-C, Liang R, Kwong Y-L.Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone. American Journal of Hematology 81: 471-473, No. 6, Jun 2006 - Hong Kong ...
ibuprofen dosage must be adjusted during and after treatment with mitoxantrone. Leader ibuprofen cold childrens has been formulated above with a special form conventicles of ibuprofen that varicocele is less irritating. As symbolizing the systemic exposure visit to tretinoin and its main metabolite were equivalent in laboratories the fed state as compared to the fasted state, Tretinoin (systemic) may aptly
Current drugs shortage notification for Mitoxantrone Hydrochloride Injection including reason for shortage, estimated resupply dates, and alternative drug therapy if available.
We studied 91 people who take Zofran and Mitoxantrone from FDA. Drug interactions are found. See what they are, when they happen and for whom.
Resistance to androgen deprivation is an ominous milestone in the natural history of metastatic prostate cancer:this disease state, now referred to as castration-refractory prostate cancer (CRPC), is historically associated with a median survival of less than two years. Until recently, only docetaxel (in combination with prednisone or estramustine) demonstrated a benefit in overall survival vs comparator therapy with mitoxantrone plus prednisone.[1,2] However, in the past year, compelling data in support of several promising new treatments for CRPC have been reported. The new data offer evidence-based treatment options, but also raise many questions for patient management and future clinical research. ...
The results of this single arm, Phase II clinical laboratory trial indicate that chemotherapy followed by bevacizumab yields a favorable CR rate and duration of CR in relapsed and refractory adult AMLs that are, by definition, resistant to classical antileukemic cytotoxic agents. At least part of the clinical effects are due to the initial chemotherapy. Indeed, a Phase I dose-escalation study of single high-dose mitoxantrone (40-80 mg/m2) in combination with high-dose ara-C (3 g/m2 daily ×5) yielded CRs in 7 of 18 (38%) adults with relapsed AML, with the median duration of those remissions being 4 months (36) . Nonetheless, based on prior studies of cell growth kinetics accompanying TST regimens where residual tumor cells on day 8 are viable and cycling and persist if no additional therapy is given (21, 22, 23) , the clearance of marrow blasts after bevacizumab in some patients raise the possibility that VEGF neutralization might result directly in leukemic cell death. In future clinical ...
This manuscript presents the characterization of two mutations in the MXR/BCRP/ABCP gene that were acquired during the course of drug selection and are shown to be responsible for differential drug efflux and sensitivity; this is one of the first examples of an ABC transporter exhibiting a gain of function mutation upon selection. Drug-resistant sublines overexpressing wild-type MXR/BCRP/ABCP with an arginine at position 482 can efflux mitoxantrone but not rhodamine or doxorubicin and have high resistance to topotecan and SN-38. The absence of rhodamine and doxorubicin efflux is a sharp contrast from the phenotype observed in S1-M1-80 cells, with an R482G mutation, and in MCF-7 AdVp cells with an R482T mutation. These latter two drug-resistant sublines efflux mitoxantrone, rhodamine, and doxorubicin. Cross-resistance studies with cell lines overexpressing the wild type and the two mutant genes found differences in cross-resistance profiles. Although the presence of other transporters or other ...
Significant morbidity and mortality continues to be associated with breast cancer and its treatments. Fisetin, a phytochemical that is present in many fruits and vegetables, has demonstrated anticancer activity. My research explores fisetin as a possible novel therapeutic modality for breast cancer. Breast cancer cell lines (MDA-MB-468, MDA- MB-231, MCF-7, T47-D, SKBR-3; mitoxantrone-resistant (MITX) and paclitaxel- resistant (Tx400) cell lines) were exposed to fisetin and cell survival was assessed by MTT, crystal violet, acid phosphatase, and colony-forming assays. Normal cells (human mammary epithelial cells, fibroblasts, human umbilical vein endothelial cells) were used as negative controls. The mechanism of action of fisetin was explored using cell cycle analysis and assays for apoptosis/necrosis, including Annexin V-propidium iodide staining and LDH-release. Apoptosis induction pathways were studied using Western blotting, as well as caspase inhibitors and cell viability assays. Flow ...
ATP-binding family G2 (ABCG2) transporters are known to produce multidrug resistance (MDR) and limit successful cancer chemotherapy. Using molecular modeling, we obtained data indicating that highly potent and selective dopamine (DA) D3 receptor antagonists had significant docking scores for the active site of the ABCG2 transporter. In this in vitro study, we determined the effect of the D3 receptor antagonists (PG01037, NGB2904, SB-277011A, and U99194) on MDR resulting from the overexpression of ABCG2 transporters. The D3 receptor antagonists alone did not significantly affect the viability of HEK293/ABCG2, H460/MX-20, S1-M1-80 or A549-MX-10 cells, which overexpress ABCG2 transporters. However, the D3 receptor antagonists (PG01037, NGB2904, SB-277011A, and U99194) significantly increased the efficacy of the anticancer drugs mitoxantrone and doxorubicin in the above mentioned cell lines. Efflux studies indicated that both PG01037 and NGB2904 significantly decreased the efflux of rhodamine 123 ...
Bcrp1-mediated DMF-MX interactions occur both in vitro and in vivo. 5,7-DMF represents a novel and very promising chemosensitizing agent for the BCRP-mediated MDR due to its low toxicity and potent BCRP inhibition.
See also Warning section. Nausea, vomiting, diarrhea, headache, or unusual tiredness may occur. In some cases, your doctor may prescribe medication to prevent or relieve nausea and vomiting. Eating several small meals, not eating before treatment, or limiting activity may help lessen some of these effects. If these effects persist or worsen, tell your doctor or pharmacist promptly. Severe nausea, vomiting, or diarrhea may infrequently result in a loss of too much body water (dehydration). Contact your doctor promptly if you notice any symptoms of dehydration such as unusual decreased urination, unusual dry mouth/increased thirst, lack of tears, dizziness/lightheadedness, or pale/wrinkled skin. Temporary hair thinning/loss may occur. Normal hair growth should return after treatment has ended. This medication may cause your urine to turn blue-green. The white part of your eyes may also turn a bluish color. These effects are temporary, normal, and harmless. Many people using this medication have ...
REFERENCES NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National
As a member of the wwPDB, the RCSB PDB curates and annotates PDB data according to agreed upon standards. The RCSB PDB also provides a variety of tools and resources. Users can perform simple and advanced searches based on annotations relating to sequence, structure and function. These molecules are visualized, downloaded, and analyzed by users who range from students to specialized scientists.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites ...
Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means. Please consult a qualified health professional for more detailed information.Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries.If you encounter technical difficulties in viewing our product information please contact Pfizer.ca
Purpose: To elucidate any differences in the exposure-response of alvocidib (flavopiridol) given by 1-hour bolus or a hybrid schedule (30-minute bolus followed by a 4-hour infusion) using a flavopiridol/cytosine arabinoside/mitoxantrone sequential protocol (FLAM) in patients with acute leukemia. The hybrid schedule was devised to be pharmacologically superior in chronic leukemia based on unbound exposure.. Experimental Design: Data from 129 patients in three FLAM studies were used for pharmacokinetic/pharmacodynamic modeling. Newly diagnosed (62%) or relapsed/refractory (38%) patients were treated by bolus (43%) or hybrid schedule (57%). Total and unbound flavopiridol concentrations were fit using nonlinear mixed-effect population pharmacokinetic methodologies. Exposure-response relationships using unbound flavopiridol AUC were explored using recursive partitioning.. Results: Flavopiridol pharmacokinetic parameters were estimated using a two-compartment model. No pharmacokinetic covariates were ...
To determine the time to progression produced by the combination of Novantrone (mitoxantrone) and Erbitux (cetuximab) versus Novantrone alone in metastatic
TY - JOUR. T1 - Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. AU - Colleoni, M.. AU - Nole, F.. AU - Di Bartolomeo, M.. AU - De Braud, F.. AU - Bajetta, E.. PY - 1992. Y1 - 1992. N2 - Patients affected by hepatocellular carcinoma (HCC) with unfavorable prognostic factors have limited therapeutic options due to moderate responsiveness to chemotherapeutic agents and lack of compliance with such treatments. In this study the feasibility and efficacy were evaluated of a treatment with mitoxantrone (dihydroxyanthracenedione, DHAD), 12 mg/m2 i.v. on day 1 every 3 weeks. We included 18 patients with poor-risk HCC ineligible for our other trials in relation to their performance status [8], pretreatments [6], age over 70 years [5], severe concomitant illness [6], and altered blood count [platelets 3) [8]. Of 17 evaluable cases, there were 4 partial remissions (23%) (95% confidence interval, 10-47%), 6 no changes, and 7 progressions. There were no ...
Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA.Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 71: 457-458, No. 6, 5 Aug 2008 - SpainGoogle Scholar ...
Mitoxantrone cancer drug molecule (type II topoisomerase inhibitor). Atoms are represented as spheres and are colour coded: hydrogen (white), carbon (grey), nitrogen (blue), oxygen (red). Illustration. - Stock Image F012/9242
55345-44-3 - QFYZUUMEXXFCKY-UHFFFAOYSA-N - 9,10-Anthracenedione, 1,5-bis((4-phenoxyphenyl)amino)- - Similar structures search, synonyms, formulas, resource links, and other chemical information.
29311-94-2 - SYZOCKFTUCTLFQ-UHFFFAOYSA-N - 9,10-Anthracenedione, 1,4-bis((3-chloro-2-hydroxypropyl)amino)- - Similar structures search, synonyms, formulas, resource links, and other chemical information.
TY - JOUR. T1 - Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). AU - Advani, Ranjana. AU - Saba, Hussain I.. AU - Tallman, Martin S.. AU - Rowe, Jacob M.. AU - Wiernik, Peter H.. AU - Ramek, Joseph. AU - Dugan, Kathleen. AU - Lum, Bert. AU - Villena, Jenny. AU - Davis, Eric. AU - Paietta, Elisabeth. AU - Litchman, Manuel. AU - Sikic, Branimir I.. AU - Greenberg, Peter L.. PY - 1999/2/1. Y1 - 1999/2/1. N2 - A potential mechanism of chemotherapy resistance in acute myeloid leukemia (AML) is the multidrug resistance (MDR-1) gene product P- glycoprotein (P-gp), which is often overexpressed in myeloblasts from refractory or relapsed AML. In a multicenter phase II clinical trial, 37 patients with these poor risk forms of AML were treated with PSC 833 (Valspodar; Novartis Pharmaceutical Corporation, East Hanover, NJ), a potent inhibitor of the MDR-1 efflux pump, plus mitoxantrone, etoposide, and ...
In a study reported in JAMA Oncology, Eric J. Chow, MD, MPH, and colleagues found that daunorubicin was associated with decreased cardiomyopathy risk vs doxorubicin among pediatric cancer survivors, with epirubicin being approximately isoequivalent to doxorubicin. Risk associated with the anthraquinone mitoxantrone was found to be substantially higher than that with doxorubicin.. As stated by the investigators, Many pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Childrens Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin.. The objective of the multicenter cohort pooled data study was to determine optimal dose equivalence ratios for late-onset cardiomyopathy between doxorubicin and other anthracyclines and mitoxantrone. The population consisted of 20,367 ...
UNLABELLED: The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age |10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2·64, 95% CI 1·32, 5·31, p = 0·006 for OS). ALL R3 showed an
Multidrug resistance remains a major obstacle to effective treatment of patients with Acute Myelogenous Leukemia (AML). A growing body of evidence indicates that over-expression of the MDR1 gene,...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Alfa Chemistry is the worlds leading provider for special chemicals. We offer qualified products for 1594-08-7(9,10-Anthracenedione,1-hydroxy-4-[[4-[(methylsulfonyl)oxy]phenyl]amino]-),please inquire us for 1594-08-7(9,10-Anthracenedione,1-hydroxy-4-[[4-[(methylsulfonyl)oxy]phenyl]amino]-).
The National Institute of Standards and Technology (NIST) uses its best efforts to deliver a high quality copy of the Database and to verify that the data contained therein have been selected on the basis of sound scientific judgment. However, NIST makes no warranties to that effect, and NIST shall not be liable for any damage that may result from errors or omissions in the Database ...
The National Institute of Standards and Technology (NIST) uses its best efforts to deliver a high quality copy of the Database and to verify that the data contained therein have been selected on the basis of sound scientific judgment. However, NIST makes no warranties to that effect, and NIST shall not be liable for any damage that may result from errors or omissions in the Database ...
ALL is the most frequent malignancy in childhood and has favourable event-free and overall survival rates. About 15% of patients suffer relapse. At relapse prognosis is much inferior (about 50% survival) leukemic clones exhibit much more resistance to conventional chemotherapy. Patients with relapse require treatment intensification and different therapeutic strategies. At relapse, new targeted agents can provide the chance for better cure rates and need to be investigated in prospective controlled trials before they may be even eligible for frontline treatment strategies. The IntReALL SR 2010 trial is designed to achieve 2 major aims: Establishment of the best available standard chemotherapy treatment. This is addressed with the randomization of the 2 best developed strategies for treatment of childhood relapsed ALL, the German ALL-REZ BFM 2002 Protocol with the Protocol II IDA arm, and the British ALL-R3 protocol with the mitoxantrone arm. This randomization allows confirming the feasibility ...
Scheithauer, W., Temsch, E.M., Jakesz, R. (1987) Preclinical evaluation of synergistic drug combinations of mitoxantrone potentially active against human colorectal and gastric adenocarcinoma. In: Progress in Antimicrobial and Anticancer Chemotherapy. Ecomed Verlag, Landsberg, BRD, pp. 814-816 ...
Chemotherapy, Iron, Administration, Cell, Cell Culture, Cell Viability, Cells, Concentrations, Culture, Drug Targeting, Drugs, Flow Cytometry, Immune System, Jurkat Cell, Jurkat Cells, Leukocytes, Magnetic, Magnetic Field, Mitoxantrone, Nanoparticles
Used by most sailors on the PWA TOUR, the Mono-Button Mast Base and Extension System (MXT) has been designed to offer a secure, heavy duty connection and ease of operation. The MXT Extensions are fully integrated with stainless steel cleat/pulley bottom assemblies offering the best weight to stiffness ratio and creatin
Hi, Im new to TIMS, but not to MS or other boards. I was dxd 9 yrs ago with MS. Have tried ABCR and Novantrone, the latter being the only effective in slowing progression. Still, I had lots of other ...
StarTech.com 6ft Straight Through Serial Cable - DB9 M/F (MXT100) at great prices. Full product description, technical specifications and customer reviews from BT Business Direct
Do allergy eye drops make the pupil larger - Do allergy eye drops make the pupil larger? Should Not. They should not cause pupil dilation unless you are using a vasoconstricting agent (visine) when the drug wears off it can cause pupil dilation.
Anthracenediones (Mitoxantrone · Pixantrone). The second main approach involves ethnobotany, the study of the general use of ...
Mitoxantrone is an immunosuppressant also used in cancer chemotherapy which was approved for MS in the year 2000; whereas ... Mitoxantrone therapy may be associated with immunosuppressive effects and liver damage; however its most dangerous side effect ... Mitoxantrone has shown positive effects in people with a secondary progressive and progressive relapsing courses. It is ... May 2013). "Mitoxantrone for multiple sclerosis". The Cochrane Database of Systematic Reviews. 5 (5): CD002127. doi:10.1002/ ...
Antineoplastics used in the treatment of cancer, such as mitoxantrone, pixantrone, and the anthracyclines ...
Other clinically used drugs in the anthracycline group are pirarubicin, aclarubicin, and mitoxantrone. The mechanisms of ... Koeller J, Eble M (1988). "Mitoxantrone: A novel anthracycline derivative". Clinical Pharmacy. 7 (8): 574-81. PMID 3048848. ... mitoxantrone and teniposide. The second group, catalytic inhibitors, are drugs that block the activity of topoisomerase II, and ...
Mitoxantrone, whose use is limited by severe adverse effects, is a third-line option for those who do not respond to other ... 662-. ISBN 978-1-4557-0738-6. Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G (May 2013). "Mitoxantrone for ... As of 2011[update], only one medication, mitoxantrone, had been approved for secondary progressive MS. In this population ... Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW (May 2010). "Evidence Report: The efficacy and safety of mitoxantrone ( ...
MITOXANTRONE HYDROCHLORIDE 333. MIZOLASTINE 334. MOCLOBEMIDE 335. MOMETASONE FUROATE 336. MONTELUKAST SODIUM ...
This led to the identification of the mitoxantrone which is classed as an anthracenedione compound and is used in the clinic ... Evison BJ, Sleebs BE, Watson KG, Phillips DR, Cutts SM (March 2016). "Mitoxantrone, More than Just Another Topoisomerase II ...
It is usually lethal, but it has been found to be responsive to Mitoxantrone and Alemtuzumab, and it has also been responsive ... monthly mitoxantrone or cyclophosphamide) either alone or in combination with IFN beta or GA.[citation needed] Marburg variant ... "Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone". Journal of Neuroimaging. 14 (1): 58-62. doi:10.1111/j.1552- ...
As of 2011[update], only one medication, mitoxantrone, has been approved for secondary progressive MS.[86] In this population ... mitoxantrone, natalizumab, fingolimod, teriflunomide,[67][68] dimethyl fumarate,[69] alemtuzumab,[70][71] ocrelizumab,[72] ... Mitoxantrone, whose use is limited by severe adverse effects, is a third-line option for those who do not respond to other ... from mitoxantrone,[87][93] and progressive multifocal leukoencephalopathy occurring with natalizumab (occurring in 1 in 600 ...
One study showed that treatment with docetaxel with prednisone prolonged life from 16.5 months for those taking mitoxantrone ... "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer". New England Journal of Medicine. 351 ( ...
October 2004). "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer". N. Engl. J. Med. 351 ( ... to improved survival rate as well as improved quality of life and reduction of pain compared with treatments with mitoxantrone ...
... has been combined with Mitoxantrone in such a way that every course of Mitoxantrone is followed by GA treatment. It has yielded ... Only Mitoxantrone has been approved for them, but most of the previous pipeline drugs have been or will be tried on it at some ... Mitoxantrone and Beta-interferon: This combination has worked in some cases but not in others Beta-interferon and Copaxone: ... "United Kingdom early Mitoxantrone Copaxone trial". Archived from the original on 2015-06-01. Retrieved 2020-04-09. Vollmer T, ...
Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R (July 2006). "Study of mitoxantrone for ...
These include: Bleomycin, chlorambucil, cyclophosphamide, cytarabine, doxorubicin, lomustine, mitoxantrone, topotecan, and ...
Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R (July 2006). "Study of mitoxantrone for ... mitoxantrone, intravenous immunoglobulin (IVIG), Rituximab, Soliris and cyclophosphamide. The disease is known to be auto- ...
"Mitoxantrone treatment in a patient with multiple sclerosis and pattern III lesions". Clinical and Experimental Neuroimmunology ... hypoxia as recently proposed Recently it has been reported that pattern III lesions are responsive to Mitoxantrone. On the ...
Mitoxantrone Piroxantrone Showalter HD, Johnson JL, Hoftiezer JM, Turner WR, Werbel LM, Leopold WR, et al. (January 1987). " ... Losoxantrone (biantrazole) is an anthroquinone anthrapyrazole antineoplastic agent and analog of mitoxantrone. It is also ...
Gopinath SC, Matsugami A, Katahira M, Kumar PK (2005). "Human vault-associated non-coding RNAs bind to mitoxantrone, a ...
... was associated with more grade 3-4 neutropenia (81.7%) than mitoxantrone (58%). Common adverse effects with ... median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving mitoxantrone. ... is markedly enhanced with cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA (ClinicalTrials.gov ...
"Designing porous silicon-based microparticles as carriers for controlled delivery of mitoxantrone dihydrochloride". Journal of ...
Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C (November 2007). "Mitoxantrone treatment in multiple ...
"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer". The New England ...
Only Mitoxantrone has been approved for them, but there is nothing for PPMS. At this moment several therapies are under ... Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Pia Amato M (2007). "Intravenous mitoxantrone and cyclophosphamide as ... a 2007 open label study found it equivalent to Mitoxantrone and in 2008 evidence appeared that it can reverse disability. ...
The ABCG2 gene was discovered in cell lines selected for high level resistance for mitoxantrone and no expression of ABCB1 or ... ABCG2 can export anthrocycline anticancer drugs, as well as topotecan, mitoxantrone, or doxorubicin as substrates. Chromosomal ...
Some anti-cancer drugs, like mitoxantrone and cyclophosphamide, have immunosuppressant effects that slow disease progression. ...
Second line treatment may include fludarabine, combined with cyclophosphamide and/or mitoxantrone, usually with rituximab. ...
... that had resistance to mitoxantrone. In addition, the same study showed weakened expression of vtRNA correlated to the cancer ... "Expression of Noncoding Vault RNA in Human Malignant Cells and Its Importance in Mitoxantrone Resistance". Molecular Cancer ... cells became more responsive or sensitive to mitoxantrone. Studies as such suggest that vtRNAs might have a role in blocking ...
The regimens commonly used in relapsed lymphoma include R-CHOP, R-CVP, RFM (i.e. rituximab, fludarabine, and mitoxantrone), and ... mitoxantrone; and 3) rituximab combined with another immunotherapeutic agent such as galiximab, epratuzumab (monoclonal ...
Mitoxantrone® & beta-interferon®: Ova kombinacije je bila efektivna u nekim slučajevima, i neuspešna u drugim [90] ... United Kingdom early Mitoxantrone Copaxone trial *↑ Vollmer T, Panitch H, Bar-Or A et al. (June 2008). "Glatiramer acetate ... Mitoxantrone® & Copaxone®: Nedavna studija u Velikoj Britaniji je proizvela interesantne rezultate za upotrebu kombinacije ... Kasnije, otvorena studija sprovedena 2007 godine je ustanovila da je Revimmunel® ekvivalentan sa Mitoxantrone®[60], i 2008 ...
Bezwoda, Werner; Seymour L.; Vorobiof D.A. (1992). "High dose cyclophosphamide, mitoxantrone, and VP-16 (HD-CNV) as first-line ... Ninety patients were randomised to compare two cycles of high-dose cyclophosphamide, mitoxantrone, and etoposide (HD-CNV) ... mitoxantrone, etoposide regimen for high-dose chemotherapy in women with high-risk primary breast cancer. - Weiss et al., The ... versus six to eight cycles of conventional-dose cyclophosphamide, mitoxantrone, and vincristine (CNV). The overall response ...
Mitoxantrone Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Mitoxantrone injection may harm the fetus. If you are using mitoxantrone injection to treat MS, even if you are using birth ... Mitoxantrone injection is also used with other medications to treat certain types of leukemia. Mitoxantrone injection is in a ... Before using mitoxantrone injection,. *tell your doctor and pharmacist if you are allergic to mitoxantrone injection, any other ...
Dexamethasone/fludarabine/mitoxantrone. Acute promyelocytic leukaemia and myelodysplastic syndromes: 4 case reports ... mitoxantrone, and dexamethasone. American Journal of Hematology 81: 471-473, No. 6, Jun 2006 - Hong Kong ... Dexamethasone/fludarabine/mitoxantrone. React. Wkly. 1116, 13 (2006). https://doi.org/10.2165/00128415-200611160-00037 ...
Before using mitoxantrone injection,. *tell your doctor and pharmacist if you are allergic to mitoxantrone injection or any ... Mitoxantrone injection may harm the fetus. If you are using mitoxantrone injection to treat MS, even if you are using birth ... Mitoxantrone injection is also used together with other medications to treat certain types of leukemia. Mitoxantrone injection ... Mitoxantrone injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:*nausea ...
Find information about Mitoxantrone including usage and side effects. Browse our Drug Dictionary for generic drug names and ... Mitoxantrone is a dark blue solution that may cause urine to appear blue-green. It may also cause the whites of the eyes to ... If mitoxantrone accidentally seeps out of the vein, it may severely damage some tissues and cause scarring. Your healthcare ... Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute ...
Do not receive mitoXANTRONE if you are allergic to mitoXANTRONE or any of the ingredients in mitoXANTRONE. See the end of this ... MITOXANTRONE HYDROCHLORIDE (UNII: U6USW86RD0) (MITOXANTRONE - UNII:BZ114NVM5P) MITOXANTRONE. 2 mg in 1 mL. ... Mitoxantrone was clastogenic in the in vivo rat bone marrow assay. Mitoxantrone was also clastogenic in two in vitro assays; it ... MitoXANTRONE is not for people with primary progressive MS.. It is not known if mitoXANTRONE is safe and effective in children ...
MITOXANTRONE HYDROCHLORIDE. (mitoxantrone hydrochloride). This product information is intended only for residents of the United ...
"Mitoxantrone". "Mitoxantrone". Drug Information Portal. U.S. National Library of Medicine. Medicine portal. ... Mitoxantrone is a type II topoisomerase inhibitor; it disrupts DNA synthesis and DNA repair in both healthy cells and cancer ... Mitoxantrone is used to treat certain types of cancer, mostly acute myeloid leukemia. It improves the survival rate of children ... Mitoxantrone is also used to treat multiple sclerosis (MS), most notably the subset of the disease known as secondary- ...
What does MITOXANTRONE-INJ look like?. mitoxantrone 2 mg/mL Concentrate, IV ... Mitoxantrone must be given only by injection into a vein. Do not give by injection into a muscle, under the skin, or into the ... Mitoxantrone is used to treat leukemia and other cancers. It is also used to treat multiple sclerosis. It belongs to a class of ... Before using mitoxantrone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This ...
Mitoxantrone is used to treat prostate cancer and certain types of leukemia. Mitoxantrone is also used to treat the symptoms of ... Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the body. ... What is mitoxantrone?. Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the ... How is mitoxantrone given?. Mitoxantrone is injected into a vein through an IV. A healthcare provider will give you this ...
A Moderate Drug Interaction exists between doxorubicin and mitoxantrone. View detailed information regarding this drug ... mitoxantrone. Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic ... Using DOXOrubicin together with mitoXANTRONE or other chemotherapy drugs may increase the risk of side effects, especially ...
mitoxantrone 45 MG per 22.5 ML Injectable Solution. SY. 7. 197989. mitoxantrone (as mitoxantrone hydrochloride) 2 MG/ML ... Do not receive MitoXANTRONE if you are allergic to MitoXANTRONE or any of the ingredients in MitoXANTRONE. See the end of this ... MITOXANTRONE HYDROCHLORIDE (UNII: U6USW86RD0) (MITOXANTRONE - UNII:BZ114NVM5P) MITOXANTRONE. 2 mg in 1 mL. ... Mitoxantrone (N = 65). 12 mg/m2 Mitoxantrone (N = 62). * Assessed using World Health Organization (WHO) toxicity criteria.. † ...
WebMD provides information about interactions between Mitoxantrone Intravenous and immunosuppresimmunomodul-selected-multiple- ... Drugs & MedicationsMitoxantrone HCL Vial. Selected Multiple Sclerosis Agents/Immunosuppressants; Immunomodulators Interactions ...
Mitoxantrone official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions ... Do not receive Mitoxantrone if you are allergic to Mitoxantrone or any of the ingredients in Mitoxantrone. See the end of this ... Mitoxantrone. Generic name: Mitoxantrone hydrochloride. Dosage form: injection, solution. Drug class: Antibiotics / ... Mitoxantrone was clastogenic in the in vivo rat bone marrow assay. Mitoxantrone was also clastogenic in two in vitro assays; it ...
Mitoxantrone dihydrochloride ≥97% (HPLC); CAS Number: 70476-82-3; EC Number: 274-619-1; Synonym: 1,4-Dihydroxy-5,8-bis[[2-[(2- ... Mitoxantrone dihydrochloride ≥97% (HPLC) Synonym: 1,4-. Dihydroxy-. 5,8-. bis[[2-. [(2-. hydroxyethyl). amino]. ethyl]. amino] ... Mitoxantrone dihydrochloride has been used:. • to induce calreticulin surface expression in cells • as a genotoxin agent • as a ... Mitoxantrone is a cytostatic anthracenedione that intercalates in DNA and increases the incidence of double-strand breaks by ...
Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means. Please consult a qualified health professional for more detailed information.Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries.If you encounter technical difficulties in viewing our product information please contact Pfizer.ca
All statistical comparisons were against mitoxantrone.. RESULTS: As compared with the men in the mitoxantrone group, men in the ... Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.. Tannock IF1, de Wit R, Berry WR, Horti ... Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate ... The median survival was 16.5 months in the mitoxantrone group, 18.9 months in the group given docetaxel every 3 weeks, and 17.4 ...
Study Evaluating Mitoxantrone in Multiple Sclerosis. The safety and scientific validity of this study is the responsibility of ... The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in ... Mitoxantrone. Sclerosis. Multiple Sclerosis. Neoplasm Metastasis. Multiple Sclerosis, Chronic Progressive. Pathologic Processes ... Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple ...
Mitoxantrone indications, usages and related health products lists ... Mitoxantrone information about active ingredients, pharmaceutical forms and doses by Bedford Laboratories, ... Find online pharmacy, drugstore, pharma or beauty shop where to order or buy Mitoxantrone brand or generic online:. ...
Mitoxantrone is a chemotherapy drug sometimes used in MS as a disease modifying drug (DMD) to reduce the number of relapses a ... How is mitoxantrone given?. Mitoxantrone is given in hospital by infusion into the vein. The infusion takes 5-15 minutes and ... How mitoxantrone works. Mitoxantrone appears to work by suppressing the bodys immune system for the period of treatment, ... Mitoxantrone research. A study published in 2016 evaluated the effectiveness and safety of mitoxantrone use in people with ...
"Stage II is a randomized phase II study of ACM versus CM (cytarabine and mitoxantrone only) in MCL-1-dependent R/R AML patients ... Home , January 20, 2019 - Volume 41 - Issue S2 , Sequential Alvocidib Followed by Cytarabine + Mitoxantrone i... ... "Cytarabine and mitoxantrone, S-phase-dependent cytotoxic agents, are administered 72 hours after alvocidib dosing to ... "The regimen of alvocidib, followed by cytarabine and mitoxantrone (ACM), has been investigated in serial phase I and II studies ...
Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells.. Futscher BW1, Abbaszadegan MR, Domann F ... To determine whether mitoxantrone-selected multidrug resistance was due to overexpression of MRP, we examined the expression of ... Mitoxantrone, an anthracenedione antitumor agent, frequently selects for non-P-glycoprotein-mediated multidrug resistance in in ... Results from these experiments suggest that overexpression of MRP does not appear to play a primary role in mitoxantrone- ...
Indications for Mitoxantrone HCl: Reduction of neurologic disability and/or frequency of clinical relapses in secondary ( ... Indications for Mitoxantrone HCl: Treatment of pain in advanced hormone-refractory prostrate cancer in combination with ... Indications for Mitoxantrone HCl: Acute nonlymphocytic leukemia (ANLL) in combination with other approved drugs. ... Mitoxantrone (as HCl) 2mg/mL; soln for IV infusion after dilution; preservative-free. ...
As such, he is ideally suited to comment on the attributes of mitoxantrone (Novantrone) in the treatment of malignant lymphoma. ... At the University of Texas M. D. Anderson Cancer Center (MDACC),we did not play a key role in the development of mitoxantrone ... In 1988, mitoxantrone was integrated into a 10-drug front-lineprogram for indolent lymphoma that was also called alternating ... In conclusion, mitoxantrone has earned its place in thearmamentarium of agents that are effective in patients with non- ...
Sanz MA.Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. Neurology 71: 457-458, No. 6, 5 Aug ...
Drug: Etoposide, Mitoxantrone, Clofarabine Cohort 1: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses ... Drug Information available for: Etoposide Mitoxantrone Mitoxantrone hydrochloride Etoposide phosphate Clofarabine Genetic and ... Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias. The safety and scientific validity of ... Cohort 4: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (5 doses); Clofarabine (Days 2-6)30 mg/m2. In the ...
Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives. Zhang, W., Wan, X., Huang, N.. To be ... Crystal structure of Ser/Thr kinase Pim1 in complex with Mitoxantrone derivatives. *DOI: 10.2210/pdb4RC4/pdb ...
Share your medication, wellness, weight loss or disease stories. Search our drug database and user posts on thousands of drugs, diseases and other conditions
Mitoxantrone) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, ... Oncotron (Mitoxantrone) Drug Price and Information. Oncotron is an antineoplastic agent, prescribed for metastatic breast ...
Mitoxantrone cancer drug molecule (type II topoisomerase inhibitor). Atoms are represented as spheres and are colour coded: ... Caption: Mitoxantrone cancer drug molecule (type II topoisomerase inhibitor). Atoms are represented as spheres and are colour ... mitoxantrone, mitozantrone, model, molecular, molecule, multiple, nitrogen, nobody, oxygen, pharma, pharmaceutical, ...
To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of ... OBJECTIVE: To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a ...
  • Additional doses of mitoxantrone should not be administered to multiple sclerosis patients who have experienced either a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy. (nih.gov)
  • Mitoxantrone is also used to treat the symptoms of relapsing multiple sclerosis. (cigna.com)
  • The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients. (clinicaltrials.gov)
  • Mitoxantrone (MTX) and Rituximab (RTX) are successfully used for treatment of multiple sclerosis (MS) and can be combined to increase efficacy. (hindawi.com)
  • This is an update of the Cochrane review "Mitoxantrone for multiple sclerosis" (published on Cochrane Database of Systematic Reviews 2013, Issue 5). (cochrane.org)
  • Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients. (cochrane.org)
  • Mitoxantrone treats certain types of cancer and certain forms of multiple sclerosis (MS). It can cause hair loss and nausea. (rxwiki.com)
  • Mitoxantrone is a prescription medication used to decrease the number of symptoms and slow the development of disability in those with certain forms of multiple sclerosis (MS). Mitoxantrone injection is also used to relieve pain in people with advanced prostate cancer. (rxwiki.com)
  • BACKGROUND/AIMS Mitoxantrone, a cytotoxic drug used for the treatment of malignancy and multiple sclerosis, is at least in part effective by triggering apoptosis. (semanticscholar.org)
  • Mitoxantrone for multiple sclerosis. (semanticscholar.org)
  • Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. (biomedsearch.com)
  • OBJECTIVE: The chemotherapeutic agent mitoxantrone was approved for use in multiple sclerosis (MS) in 2000. (biomedsearch.com)
  • Mitoxantrone is used for aggressive multiple sclerosis (MS) but concerns about safety, including cardiotoxicity and other laboratory measures prevail. (mssociety.ca)
  • The multiple sclerosis drug mitoxantrone may be associated with an increased risk of colorectal cancer, according to a study published in Neurology, the medical journal of the American Academy of Neurology. (thisisms.com)
  • Is there a new place for mitoxantrone in the treatment of multiple sclerosis? (thisisms.com)
  • To compare the clinical and neuroradiological efficacy of mitoxantrone (MTX) in various forms of multiple sclerosis (MS), to ascertain whether there is a new place for the drug in the treatment regimen of the disease, as well as to determine its safety profile. (thisisms.com)
  • Due to the increasing availability of new immunomodulatory therapies in multiple sclerosis (MS), there is a strong need to re-identify clinical variants and stages of the disease in which mitoxantrone (MTX) can be the most effective form of treatment. (thisisms.com)
  • This preliminary study was designed to investigate the evidence-based mitoxantrone therapy results in patients with multiple sclerosis (MS). (kowsarpub.com)
  • The aromatic organic compound, mitoxantrone (an anthraquinone, anthracenedione or dioxoanthracene) is useful in the secondary progressive phase (SP) of multiple sclerosis (MS) ( 1 ). (kowsarpub.com)
  • Mitoxantrone is also approved for use in relapsing and progressive multiple sclerosis. (nih.gov)
  • Mitoxantrone is administered intravenously in varying doses typically ranging from 12 to 14 mg/m 2 at intervals of every 3 months (multiple sclerosis) or in monthly cycles (prostate cancer and leukemia). (nih.gov)
  • A 44 year old woman with primary, progressive multiple sclerosis developed jaundice 8 weeks after starting mitoxantrone (10 mg every 4 weeks) and piracetam (3 gm daily). (nih.gov)
  • OBJECTIVE: To investigate the secondary progressive multiple sclerosis (SPMS) patients treated with mitoxantrone (MIT) and discuss the effectiveness and side effects of MIT. (tjn.org.tr)
  • Mitoxantrone is a chemotherapy drug that is used to treat multiple sclerosis (MS) and certain types of cancer. (medicalnewstoday.com)
  • Mitoxantrone is considered an antineoplastic agent and a multiple sclerosis agent. (medicalnewstoday.com)
  • Mitoxantrone has been administered to 149 patients with multiple sclerosis in two randomized clinical trials, including 21. (pfizermedicalinformation.com)
  • Mitoxantrone Hydrochloride is indicated for reducing neurologic disability and /or the frequency of clinical relapses in patients with secondary chronic progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). (pharmaquest.biz)
  • As such, he is ideally suited to comment on the attributes of mitoxantrone (Novantrone) in the treatment of malignant lymphoma. (cancernetwork.com)
  • Novantrone® (mitoxantrone hydrochloride) is a synthetic anticancer agent for intravenous use. (multiplesclerosis.net)
  • The active ingredient in Novantrone is mitoxantrone hydrochloride. (multiplesclerosis.net)
  • The concentrate is a sterile, nonpyrogenic, dark blue aqueous solution containing mitoxantrone hydrochloride equivalent to 2 mg/mL mitoxantrone free base, with the following inactive ingredients: sodium chloride (0.800% w/v), sodium acetate (0.005% w/v), acetic acid (0.046% w/v), and water for injection. (nih.gov)
  • Mitoxantrone has active ingredients of mitoxantrone hydrochloride . (ehealthme.com)
  • Mitoxantrone (mitoxantrone hydrochloride) is often used to treat acute myeloid leukaemia. (ehealthme.com)
  • OBJECTIVES: I. Determine the toxicities of escalating doses of flavopiridol administered by "hybrid" bolus-infusion schedule and given in timed sequence with cytarabine and mitoxantrone hydrochloride in patients with refractory or relapsed acute leukemia. (checkorphan.org)
  • Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9. (checkorphan.org)
  • A history of hypersensitivity or allergic reaction to mitoxantrone hydrochloride. (multiplesclerosis.net)
  • Mitoxantrone hydrochloride is an MS infusion treatment as well as a chemotherapy drug used to treat cancer. (healthline.com)
  • The regimen of alvocidib, followed by cytarabine and mitoxantrone (ACM), has been investigated in serial phase I and II studies in both newly diagnosed and relapsed/refractory acute myeloid leukemia (R/R AML) patients," Zeidner noted. (lww.com)
  • Stage II is a randomized phase II study of ACM versus CM (cytarabine and mitoxantrone only) in MCL-1-dependent R/R AML patients with a primary objective of assessing CR rates between ACM and CM. (lww.com)
  • Determine the clinical effectiveness of bevacizumab, cytarabine, and mitoxantrone in patients with poor-risk hematologic malignancies. (knowcancer.com)
  • This study explored the role of mitochondrial metabolism in chemotherapy response and determined the MTD, efficacy, and safety of CPI-613 combined with high-dose cytarabine and mitoxantrone in patients with relapsed or refractory acute myeloid leukemia. (aacrjournals.org)
  • A phase I study of CPI-613 plus cytarabine and mitoxantrone was conducted in patients with relapsed or refractory AML. (aacrjournals.org)
  • The Toxicities of Administration of PD 0332991 in Combination With Cytarabine and Mitoxantrone. (druglib.com)
  • Drugs used in chemotherapy, such as flavopiridol, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (checkorphan.org)
  • This phase I trial is studying the side effects, best dose, and best schedule for flavopiridol when given together with cytarabine and mitoxantrone in treating patients with relapsed or refractory acute leukemia. (checkorphan.org)
  • Tell your doctor and pharmacist if you are taking or have ever received certain cancer chemotherapy medications such as daunorubicin (Cerubidine), doxorubicin (Doxil), epirubicin (Ellence), or idarubicin (Idamycin), or if you have ever been treated with mitoxantrone in the past. (medlineplus.gov)
  • Using DOXOrubicin together with mitoXANTRONE or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. (drugs.com)
  • Inevitably, mitoxantrone must be compared with doxorubicin,which remains the standard against which anthracycline analogs are evaluated.Dr. Armitage reviews the pertinent literature concerning the cardiotoxicpotential of these agents, as well as the literature that defines the doses ofdoxorubicin and mitoxantrone that have equivalent myelosuppressive toxicity. (cancernetwork.com)
  • While the toxicities associated with its use are significantly less than those observed following treatment with the widely used doxorubicin, mitoxantrone cardiotoxicity is clearly a substantial clinical problem. (openrepository.com)
  • Similar protection is observed against doxorubicin and the oxidized form of mitoxantrone, but not against the non-hydroxylated analog of mitoxantrone, ametantrone. (openrepository.com)
  • Mitoxantrone (mye tox' an trone) is an antineoplastic antibiotic that is a synthetic derivative of doxorubicin and is considered an anthracenedione. (nih.gov)
  • Who Should Not Take This Medication You should not take this medication if you are allergic to mitoxantrone, any of its components, or other medications that are similar to mitoxantrone, including doxorubicin, epirubicin, daunorubicin, idarubicin. (dvohmg.com)
  • Patients who received more than one anthracycline prior to study entry should have each individual agent cumulative dose converted to doxorubicin equivalent and added together (eg, a patient who received cumulative dose of Daunorubicin at 200 mg/m2 and Mitoxantrone 48 mg/m2 has a total doxorubicin dose equivalent of 358.6 mg/m2 (200 mg/m2 x 0.833 + 48 mg/m2 x 4). (trialbulletin.com)
  • and problems with vision, speech, and bladder control), your doctor will also perform certain tests before each dose of mitoxantrone injection and yearly after you have completed your treatment. (medlineplus.gov)
  • Because of the risk of cardiomyopathy, mitoxantrone carries a limit on the cumulative lifetime dose (based on body surface area) in MS patients. (wikipedia.org)
  • Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. (nih.gov)
  • A study published in 2014 found that the higher the total dose of mitoxantrone given over a period of time, the more chance of cardiac dysfunction. (mstrust.org.uk)
  • The purpose of this study is to establish toxicity and a maximum tolerated dose recommended phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of relapsed or refractory acute leukemias. (clinicaltrials.gov)
  • Patients will proceed to treatment through a series of cohorts with the three drugs being delivered over five days beginning with a dose of Etoposide 100 mg/m2 on days 1-5,Mitoxantrone 8 mg/m2 days 1-3, and clofarabine at 20 mg/m2 IV on days 2-6. (clinicaltrials.gov)
  • Presuming this and subsequent cohorts are tolerable and no more than 1 patient per cohort develops DLT, MTD patients will be treated in cohorts of 3-6 patients up to a final dose level of Etoposide 100 mg/m2 on days 1-5,Mitoxantrone 8 mg/m2 days 1-5, and Clofarabine at 30 mg/m2 IV on days 2-6. (clinicaltrials.gov)
  • The recommended dose and dosing schedule of mitoxantrone varies according to the specific condition being treated, the response to therapy, the other medications or treatments being used and the body size of the person receiving treatment. (medbroadcast.com)
  • The phase I portion of the trial will determine the maximum tolerated dose of gemtuzumab ozogamicin combined with mitoxantrone and etoposide and the phase II portion of the trial will determine the efficacy and safety of the combined regimen in patients with AML. (clinicaltrials.gov)
  • A retrospective review of patients treated with mitoxantrone by standard protocol (maximum cumulative dose=120mg/m2 ) was conducted. (mssociety.ca)
  • In addition, mitoxantrone significantly decreased the viability of breast cancer cells in a dose-dependent manner and inhibited the kinase activity of FAK and Y56/577 FAK phosphorylation at 10-20 μM. (eurekaselect.com)
  • The product label recommends regular monitoring of serum aminotransferase levels before each monthly or every-three-month infusion of mitoxantrone therapy, but dose modifications or discontinuation are rarely necessary. (nih.gov)
  • We may have to adjust the dose of mitoxantrone depending on your blood counts. (blogspot.com)
  • Mitoxantrone is given intravenously by an infusion the dose you receive will be dependent on which regime your consultant wishes to prescribe for you. (blogspot.com)
  • Mitoxantrone is dark blue in colour, so it may turn your urine a blue-green colour for a few days after each dose. (blogspot.com)
  • The risk of developing leukemia is higher in patients 1) who are receiving other chemotherapy medications in combination with mitoxantrone, 2) who have received a lot of previous chemotherapy, or 3) who are receiving a high dose of mitoxantrone. (dvohmg.com)
  • Anna B. Halpern from Clinical Research Division, Fred Hutchinson Cancer Research Center/University of Washington , Seattle, WA, USA, and colleagues conducted a phase I/II trial ( NCT02044796 ) of G-CSF, cladribine, high-dose cytarabine, and dose-escalated mitoxantrone (GCLAM) in adults with newly-diagnosed acute myeloid leukemia (AML). (amlglobalportal.com)
  • Thirty-three patients were enrolled in the phase I portion of the study and received either 12 (dose level [DL] 1), 14 (DL2), 16 (DL3) or 18 (DL4) mg/m 2 /day of mitoxantrone on Day 1-3 as part of GCLAM, for cohorts including 6-12 patients. (amlglobalportal.com)
  • Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. (amlglobalportal.com)
  • Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. (trialbulletin.com)
  • 2.1 To determine the maximal tolerated dose (MTD) and/or tolerable dose of escalating doses of clofarabine starting from 20mg/m2/day to 40mg/m2/day from Day 1 to Day 5 in combination with mitoxantrone 12mg/m2/day on Day 3-6 as reinduction therapy for children, adolescents and young adults with poor risk refractory/relapsed acute leukemia or high grade NHL. (trialbulletin.com)
  • Some clinicians recommend discontinuance of mitoxantrone HCL powder (and continuation of corticosteroid therapy alone) in patients who are still responding after a cumulative mitoxantrone HCL powder dose of 140 mg/m2 due to risk of cardiac toxicity. (aasraw.com)
  • The risk of heart damage may depend on the total amount of mitoxantrone given to a person over a lifetime, so your doctor will probably limit the total number of doses you receive if you are using this medication for MS. If you experience any of the following symptoms, call your doctor immediately: difficulty breathing, chest pain, swelling of the legs or ankles, or irregular or fast heartbeat. (medlineplus.gov)
  • Because the risk for heart problems increases with the total amount of medication given, people being treated for MS have a limit on the total amount of mitoxantrone they should receive over their lifetime. (emedtv.com)
  • The risk of developing this problem increases as the total amount of mitoxantrone used over time increases (see Who Should Not Take This Medication and Precautions To Be Aware Of Before Taking This Medication). (dvohmg.com)
  • The risk of developing this problem increases as the total amount of mitoxantrone used over time increases. (dvohmg.com)
  • Mitoxantrone is FDA approved in combination with other approved drug(s) indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. (lls.org)
  • 3-7] For patients with recurrent lymphoma, mitoxantrone fitnicely into an evolving series of ifosfamide(Ifex)/etoposide regimens,[8,9,3]culminating in the MINE-ESHAP* strategy cited by Dr. Armitage. (cancernetwork.com)
  • Patients failing to enter remission may receive 4 days of therapy with Etoposide 100 mg/m2 on days 1-4,Mitoxantrone 8 mg/m2 days 1-2 or 1-4,and Clofarabine at 20-30 mg/m2 IV on days 1-4. (clinicaltrials.gov)
  • The combination of MEC (mitoxantrone, etoposide, and cytarabine) is a standard treatment option, commonly used for relapsed or refractory acute myeloid leukemia. (clinicaltrials.gov)
  • Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. (clinicaltrials.gov)
  • The purpose of this study is to investigate the combination of gemtuzumab ozogamicin, mitoxantrone and etoposide as second line therapy in patients with acute myeloid leukemia. (clinicaltrials.gov)
  • The combination of mitoxantrone and etoposide is an active regimen in refractory/relapsed AML patients. (clinicaltrials.gov)
  • In order to improve the efficacy of mitoxantrone and etoposide as second line therapy in patients with AML we proposed to conduct a phase I/II clinical trial combining gemtuzumab ozogamicin with mitoxantrone and etoposide. (clinicaltrials.gov)
  • To assess the overall survival in patients with AML treated with the combination of mitoxantrone, etoposide and gemtuzumab ozogamicin. (clinicaltrials.gov)
  • Myeloperoxidase is expressed exclusively in granulocytes and immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantrone to chemical forms that have altered DNA damaging properties. (aspetjournals.org)
  • We show here that myeloperoxidase activity leads to elevated accumulation of etoposide- and mitoxantrone-induced TOP2A and TOP2B-DNA covalent complexes in cells, which are converted to DNA double-strand breaks. (aspetjournals.org)
  • Mitoxantrone Injection, USP (concentrate) is a synthetic antineoplastic anthracenedione for intravenous use. (nih.gov)
  • Mitoxantrone is a cytostatic anthracenedione that intercalates in DNA and increases the incidence of double-strand breaks by stabilizing the cleavable complex of topoisomerase II and DNA. (sigmaaldrich.com)
  • Mitoxantrone, an anthracenedione antitumor agent, frequently selects for non-P-glycoprotein-mediated multidrug resistance in in vitro models. (nih.gov)
  • The use of the anthracenedione mitoxantrone as an antitumor agent is steadily increasing. (openrepository.com)
  • Mitoxantrone may increase your risk for developing leukemia (cancer of the white blood cells), especially when it is given in high doses or together with certain other chemotherapy medications. (medlineplus.gov)
  • When mitoxantrone injection is used to treat MS, it is usually given once every 3 months for about 2 to 3 years (for a total of 8 to 12 doses). (medlineplus.gov)
  • Mitoxantrone therapy is often accompanied by mild to moderate elevations in serum aminotransferase levels, but in typical doses it rarely causes clinically apparent, acute liver injury. (nih.gov)
  • In high doses, mitoxantrone has been associated with a high rate of jaundice, but the degree of hyperbilirubinemia has been mild, transient and not associated with significant serum enzyme elevations or evidence of hepatitis. (nih.gov)
  • Mitoxantrone injection is also used with other medications to treat certain types of leukemia. (medlineplus.gov)
  • When mitoxantrone injection is used to treat leukemia, you will continue to receive this medication based on your condition and how you respond to the treatment. (medlineplus.gov)
  • Mitoxantrone is used to treat certain types of cancer, mostly acute myeloid leukemia. (wikipedia.org)
  • Au W-Y, Chan L-C, Liang R, Kwong Y-L.Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone. (springer.com)
  • Mitoxantrone therapy in patients with MS and in patients with cancer increases the risk of developing secondary acute myeloid leukemia. (nih.gov)
  • Mitoxantrone is used to treat leukemia and other cancers. (medhelp.org)
  • Using mitoxantrone may increase your risk of other types of cancer, such as leukemia. (cigna.com)
  • Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA.Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone. (springer.com)
  • Daunorubicin and mitoxantrone considered as crucial components of almost all standard acute myeloid leukemia induction regimens. (springer.com)
  • The trial's DSMC subsequently recommended stopping accrual secondary to a higher leukemia rate in Arm 2 receiving mitoxantrone. (urotoday.com)
  • RESULTS: The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy. (biomedsearch.com)
  • CONCLUSIONS: The risk of systolic dysfunction and leukemia in patients treated with mitoxantrone is higher than suggested at the time of the previous report, although comprehensive postmarketing surveillance data are lacking. (biomedsearch.com)
  • We investigated the anthraquinone compound mitoxantrone that is used for treating certain cancer types like leukemia and lymphoma with magnetic tweezers as a single molecule nanosensor. (springer.com)
  • 9 Similar results were reported in patients with chronic lymphocytic leukemia (CLL) and FL in progression/relapse, treated with fludarabine, cyclophosphamide and mitoxantrone (FCM). (haematologica.org)
  • To prevent the serious adverse effects of mitoxantrone, such as acute leukemia and secondary hematologic cancers, pharmacotherapy outcome, using disease modifying drugs, should focus on rate and severity of relapses within Iranian pateints with MS. (kowsarpub.com)
  • in 2013, reviewed therapy-related acute leukemia in patients under therapy with mitoxantrone and highlighted the need for close hematologic monitoring during and after therapy ( 7 ). (kowsarpub.com)
  • Mitoxantrone is an antineoplastic antibiotic that is used in the treatment of acute leukemia, lymphoma, prostate and breast cancer. (nih.gov)
  • Mitoxantrone has potent antitumor effects in vitro and has been evaluated in leukemia, lymphoma and several solid tumors in humans. (nih.gov)
  • Mitoxantrone was approved for use in the United States in 1987 and current indications include acute non-lymphocytic leukemia and advanced prostate cancer. (nih.gov)
  • Mitoxantrone may increase your risk for developing a type of leukemia known as acute myeloid leukemia ( AML ). (emedtv.com)
  • For acute nonlymphocytic leukemia and prostate cancer, mitoxantrone targets cells that divide quickly. (medicalnewstoday.com)
  • The development of leukemia has been reported in patients receiving mitoxantrone. (dvohmg.com)
  • Mitoxantrone is used alone or in combination with other chemotherapy medications to treat adults with prostate cancer and certain types of leukemia (acute myeloid leukemia). (dvohmg.com)
  • In patients with acute myeloid leukemia, mitoxantrone is used as a component of various chemotherapy treatments to help bring on remission from the disease. (dvohmg.com)
  • Because cladribine, ara-C, and mitoxantrone chemotherapy medications work best when cells are dividing, GCSF causes more AML leukemia cells to die from chemotherapy. (chemoexperts.com)
  • The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL). (trialbulletin.com)
  • To determine the overall complete and partial response rate (OR) of the combination of mitoxantrone and clofarabine as reinduction therapy for children, adolescents and young adults with refractory/relapsed acute leukemia or high grade NHL. (trialbulletin.com)
  • Mitoxantrone activated NFkappaB and stimulated IkappaBalpha degradation in the promyelocytic leukemia cell line HL60 but not in the variant cells, HL60/MX2 cells, which lack the beta isoform of topoisomerase II and express a truncated alpha isoform that results in an altered subcellular distribution. (umassmed.edu)
  • Parallel to that front-line strategy, the simpler FNDregimen (fludarabine [Fludara], mitoxantrone, dexamethasone) was devised forpatients with relapsed indolent lymphoma. (cancernetwork.com)
  • Patients in group 2 will receive fludarabine on Days 1-3, mitoxantrone on Day 1, and dexamethasone on Days 1-5 of each 28-day cycle. (knowcancer.com)
  • Design and Methods This is a phase II trial including 120 patients (≤65 years) treated with 6 cycles of fludarabine, cyclophosphamide and mitoxantrone (FCM). (haematologica.org)
  • in 1994 showed that fludarabine, mitoxantrone and dexamethasone (FND) induces a high response rate in relapsed FL. (haematologica.org)
  • Treatment comprised: fludarabine 25 mg/m 2 days 1-3, mitoxantrone 10 mg/m 2 day 1, and dexamethasone 20 mg days 1-5. (elsevier.com)
  • Treatment comprised: fludarabine 25 mg/m2 days 1-3, mitoxantrone 10 mg/m2 day 1, and dexamethasone 20 mg days 1-5. (elsevier.com)
  • This is not a complete list of mitoxantrone drug interactions. (rxwiki.com)
  • Drug interactions are reported among people who take Zofran and Mitoxantrone together. (ehealthme.com)
  • This review analyzes the effectiveness and drug interactions between Zofran and Mitoxantrone. (ehealthme.com)
  • The interactions of mitoxantrone with DNA are unique to each of these DNA sequences. (jbsdonline.com)
  • Mitoxantrone may react with several other medications (see Drug Interactions With Mitoxantrone ) . (emedtv.com)
  • How Mitoxantrone Injection works, side effects, interactions and precautions. (navigatingcare.com)
  • The combination of mitoxantrone and prednisone is approved as a second-line treatment for metastatic hormone-refractory prostate cancer. (wikipedia.org)
  • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (nih.gov)
  • Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. (nih.gov)
  • From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. (nih.gov)
  • When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plus prednisone. (nih.gov)
  • High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. (semanticscholar.org)
  • Chicago, IL (UroToday.com) Dr. Maha Hussain and colleagues presented their phase III results of a trial assessing adjuvant androgen deprivation therapy (ADT) +/- mitoxantrone + prednisone (MP) for patients with high risk prostate cancer after radical prostatectomy at the ASCO 2017 prostate cancer poster session. (urotoday.com)
  • Randomization was to Arm 1 - ADT (bicalutamide + goserelin for 2 years) or Arm 2 - ADT + 6 cycles of mitoxantrone 12 mg/m2 + prednisone 5 mg BID. (urotoday.com)
  • Objective: To compare pain palliation as the primary endpoint for cabozantinib versus mitoxantrone-prednisone in men with mCRPC and symptomatic bone metastases using patient-reported outcome measures. (urotoday.com)
  • Intervention: Cabozantinib 60 mg once daily orally versus mitoxantrone 12 mg/m2 every 3 wk plus prednisone 5 mg twice daily orally. (urotoday.com)
  • mitoxantrone-prednisone: N = 58). (urotoday.com)
  • There was no significant difference in the pain response with cabozantinib versus mitoxantrone-prednisone: the proportions of responders were 15% versus 17%, a2% difference (95% confidence interval:16% to 11%,p = 0.8). (urotoday.com)
  • Conclusions: Cabozantinib treatment did not demonstrate better pain palliation than mitoxantrone-prednisone in heavily pretreated patients with mCRPC and symptomatic bone metastases. (urotoday.com)
  • Patient summary: Cabozantinib was not better than mitoxantrone-prednisone for pain relief in patients with castration-resistant prostate cancer and debilitating pain from bone metastases. (urotoday.com)
  • This is a randomized, open-label, multi-center study comparing the safety and efficacy of XRP6258 plus prednisone to mitoxantrone plus prednisone in the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere -containing regimen. (druglib.com)
  • Men were randomized to receive either docetaxel + prednisone + custirsen (DPC) or mitoxantrone + prednisone + custirsen (MPC). (aacrjournals.org)
  • A Randomized Phase 2 Study of Human Anti-PDGFR-alpha Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-based Chemotherapy. (springer.com)
  • Rare instances of acute liver injury have been reported in patients taking mitoxantrone, including a single case of drug-rash with eosinophilia and systemic symptoms (DRESS). (nih.gov)
  • Mitoxantrone injection is also used together with steroid medications to relieve pain in people with advanced prostate cancer who did not respond to other medications. (medlineplus.gov)
  • When mitoxantrone injection is used to treat prostate cancer, it is usually given once every 21 days. (medlineplus.gov)
  • Mitoxantrone injection is used to decrease the number of symptom episodes and slow the development of disability in patients with certain forms of MS. Mitoxantrone injection is also used together with steroid medications to relieve pain in people with advanced prostate cancer who did not respond to other medications. (empowher.com)
  • Benefits Of This Medication In patients with prostate cancer, mitoxantrone, when used in combination with steroids, has been shown to be more effective in relieving pain and improving overall quality of life compared with steroids alone. (dvohmg.com)
  • Mitoxantrone Injection, USP (concentrate) should be administered under the supervision of a physician experienced in the use of cytotoxic chemotherapy agents. (nih.gov)
  • More powerful approaches to disease modification in MS include the so-called "biological therapies" or monoclonal antibodies (natalizumab, alemtuzumab, daclizumab, rituximab, and ocrelizumab) and cytotoxic drugs (cladribine and mitoxantrone) [ 3 - 6 ]. (hindawi.com)
  • Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. (semanticscholar.org)
  • Current information on the mechanism by which mitoxantrone causes toxicity in heart tissue is limited. (openrepository.com)
  • Mitoxantrone toxicity is lowered with the addition of ICRF-187, a metal chelating agent. (openrepository.com)
  • These data suggests that metal chelation is involved in the enhancement of mitoxantrone toxicity in vitro. (openrepository.com)
  • The transient ALT elevations that can occur during mitoxantrone therapy are likely due to direct toxicity of the drug or its metabolites. (nih.gov)
  • J. Cancer 82, 1300 (2000) A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone: J. Blasiak, et al. (scbt.com)
  • Mitoxantrone belongs to a group of drugs called anthracenediones. (rxwiki.com)
  • Previous publications reported 6-month course of mitoxantrone, followed by continuation treatment, such as immunomodulatory drugs, results in a speedy decrease in disease action and a constant syndrome management for at least 5 years. (kowsarpub.com)
  • Other drugs were being taken and the association with mitoxantrone was not definite (Case 1). (nih.gov)
  • The MITOXANTRONE was created to fill a need, infested by Dr. I'm not a prudent model, but the healthful vice approach fervently took a back seat to the untroubled drugs. (biz.ly)
  • MITOXANTRONE was via the whiney route on 82% and afterwards on 9% of the most pathetic issue all endogenously, but until now malleable drugs, such as asgard. (biz.ly)
  • Anti-cancer drugs, such as mitoxantrone, that target this enzyme interrupt its catalytic cycle and give rise to persistent double strand breaks, which may be lethal to a cell. (umassmed.edu)
  • Mitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFα, and IL-2. (nih.gov)
  • A pilot compound library screen revealed that the topoisomerase II poison MTX (mitoxantrone) is an inhibitor of Rac1, and also inhibits RhoA and Cdc42 in vitro . (biochemj.org)
  • In vitro analysis of the anti-cancer activity of mitoxantrone loaded on magnetic nanoparticles. (semanticscholar.org)
  • The data demonstrate that mitoxantrone decreases cancer viability, binds FAK-Kinase domain, inhibits its kinase activity, and also inhibits in vitro kinase activities of Pyk-2 and IGF-1R. (eurekaselect.com)
  • However, there is evidence to support the possibility that mitoxantrone can form a reactive intermediate in vitro. (openrepository.com)
  • An in vitro drug sensitivity assay demonstrated that one of these USP11 inhibitors, mitoxantrone, impacted PDA cell survival with an IC 50 of less than 10 nM. (elsevier.com)
  • Despite a lack of enhanced cytotoxicity in vitro , HSV-1 ICP0 null oncolytic virus KM100 with 5 μmol/L mitoxantrone provided significant survival benefit to BALB/c mice bearing Her2/neu TUBO-derived tumors. (aacrjournals.org)
  • Talk to your doctor about the risks of using mitoxantrone injection. (medlineplus.gov)
  • Some of the possible side effects of mitoxantrone include fatigue, nausea, and upper respiratory tract infections. (emedtv.com)
  • Some side effects of mitoxantrone should be reported immediately to your healthcare provider. (emedtv.com)
  • Herein we describe how the drug mitoxantrone can bind, induce folding of and stabilise i-motif forming DNA sequences, even at physiological pH. (jic.ac.uk)
  • Mitoxantrone ability to induce premature senescence in human dental pulp stem cells and human dermal fibroblasts. (semanticscholar.org)
  • mitoxantrone can induce clinical responses in adults with relapsed or refractory acute leukemias and high-risk MDS 1. (druglib.com)
  • You should not use this medication if you are allergic to mitoxantrone. (cigna.com)
  • You should not receive this medicine if you have had an allergic reaction to mitoxantrone, or if you are pregnant or breastfeeding. (limamemorial.org)
  • Mitoxantrone injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. (medlineplus.gov)
  • MS patients should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late occurring cardiotoxicity. (nih.gov)
  • Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. May 31, 2010. (mssociety.ca)
  • Characterization of mitoxantrone cardiotoxicity in cultured heart cells. (openrepository.com)
  • Thus, the goal of these studies was to describe a model system in which mitoxantrone cardiotoxicity can be studied, and begin to describe the mechanism by which mitoxantrone exerts its cardiotoxic effect. (openrepository.com)
  • Mitoxantrone also displays broad immunosuppressive activity inhibiting proliferation of all classes of lymphocytes and inducing apoptosis of antigen-presenting T cells. (sigmaaldrich.com)
  • Mitoxantrone also has immunosuppressive activity, inhibiting B cell, T cell and macrophage proliferation and decreasing tumor necrosis factor alpha and interleukin-2 secretion. (nih.gov)
  • Mitoxantrone should be given only under the supervision of a doctor with experience in the use of chemotherapy medications. (medlineplus.gov)
  • Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. (nih.gov)
  • Mitoxantrone cancer drug molecule (type II topoisomerase inhibitor). (sciencephoto.com)
  • Topoisomerase II is required for mitoxantrone to signal nuclear factor" by Martin P. Boland, Katherine A. Fitzgerald et al. (umassmed.edu)
  • Treatment of sensitive HL60 cells with mitoxantrone led to a depletion of both isoforms, suggesting the stabilization of transient DNA-topoisomerase II complexes. (umassmed.edu)
  • Mitoxantrone is a cancer medication that interferes with the growth and spread of cancer cells in the body. (cigna.com)
  • Mitoxantrone may also be used for purposes not listed in this medication guide. (cigna.com)
  • Mitoxantrone can cause nausea and vomiting, but it is important to keep using this medication even if you feel ill. (medbroadcast.com)
  • Patients who develop immunoallergic reactions to mitoxantrone should not be rechallenged with the medication. (nih.gov)
  • Although not everyone who uses the medication will have problems, most people will experience some type of mitoxantrone side effect. (emedtv.com)
  • Mitoxantrone is a pregnancy Category D medication, which means it may harm an unborn child. (emedtv.com)
  • Only a doctor with experience of giving this kind of medication should administer mitoxantrone. (medicalnewstoday.com)
  • Your doctor or healthcare provider will check your blood before starting mitoxantrone treatment to make sure that it is safe to start this medication. (dvohmg.com)
  • How This Medication Works Mitoxantrone is a chemotherapy medication that doesn't allow cancer cells, also known as tumor cells, to divide and grow normally, which leads to tumor cell death. (dvohmg.com)
  • Mitoxantrone Injection, USP (concentrate) should be given slowly into a freely flowing intravenous infusion. (nih.gov)
  • Mitoxantrone is given in hospital by infusion into the vein. (mstrust.org.uk)
  • Mitoxantrone is a drug that a healthcare provider gives in a clinical setting, as an intravenous infusion. (medicalnewstoday.com)
  • Congestive heart failure (CHF), potentially fatal, may occur either during therapy with mitoxantrone or months to years after termination of therapy. (nih.gov)
  • The pharmacokinetic and tissue distribution of mitoxantrone, with and without co-administration of 5,7-DMF or multiple flavonoid combinations, were determined in mice. (nih.gov)
  • The administration of mitoxantrone, as the stimulation remedy behind an immunomodulatory drug, is of attentive interest. (kowsarpub.com)
  • Your doctor or healthcare provider will monitor you carefully during the administration of mitoxantrone to make sure that this does not happen. (dvohmg.com)
  • Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. (biomedsearch.com)
  • OBJECTIVE: To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months. (biomedsearch.com)
  • article{2a3edb89-6fb5-406f-87d5-bb309003c418, abstract = {30 patients with malignant pleuritis were randomised to be treated, either with intrapleural instillation of mepacrine chloride or with mitoxantrone. (lu.se)
  • The most common is side effect of Mitoxantrone in patient with MS are nausea, hair thinning, loss of menstrual periods, bladder infections and mouth ulcers or sores. (blogspot.com)
  • Thus, we investigated enhancing efficacy through combination therapy with the immunogenic cell death-inducing chemotherapeutic drug, mitoxantrone. (aacrjournals.org)
  • Mitoxantrone can cause heart problems, including congestive heart failure , which can be severe enough to lead to death. (emedtv.com)
  • Mitoxantrone can cause heart problems, including congestive heart failure. (dvohmg.com)
  • Mitoxantrone injection is in a class of medications called anthracenediones. (medlineplus.gov)
  • Before you are treated with mitoxantrone, tell your doctor about all other cancer medications and treatments you have received, including radiation. (cigna.com)
  • Chemotherapeutic agents inducing immunogenic cancer cell death, such as mitoxantrone (MTX) elicit potent anticancer immune responses ( 17-19 ). (aacrjournals.org)
  • Initial experiments aimed at defining mitoxantrone mechanism of action showed that mitoxantrone likely does not stimulate a significant production of active oxygen species, or have a specific effect on mitochondrial function. (openrepository.com)
  • Although mitoxantrone inhibits lipopolysaccharide induction of many immunological factors, but the mechanism of action somewhat remains to be more understood. (kowsarpub.com)
  • 13]But the overall simplicity of the FND regimen, its efficacy, and the substantialencouraging confirmatory data from other institutions have made thefludarabine/mitoxantrone (FN) combination (with or without steroids) anappealing option for patients with indolent lymphoma. (cancernetwork.com)
  • This review was undertaken to examine the available literature on the efficacy and safety of mitoxantrone use in patients with MS since the initial report. (biomedsearch.com)
  • Second-line treatment with mitoxantrone and retreatment with docetaxel are commonly used despite limited data on safety and efficacy. (aacrjournals.org)
  • The risk of severe adverse events when using mitoxantrone, especially therapy-related acute leukaemia (TRAL), are also greater than previously thought. (mstrust.org.uk)